All In Biotech

Drug Trial Radar · NCT02817360

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial

Last checked: Nov 19, 2026Latest source record: Mar 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,400

Planned (sponsor's estimate)

Start

Feb 2016

Primary completion

Dec 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Martin HuelsmannAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose and rationale The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population of patients with Type 2 diabetes mellitus (T2DM) with no evidence of a preexisting cardiac disease. An additional aim is to demonstrate an interaction between concentrations of amino-terminal pro-B type natriuretic peptide (NT-proBNP as a surrogate of imminent cardiac risk) and treatment effects and the economic impact of the intervention overall and in the biomarker stratified subgroups. Primary objective Superiority of high dose treatment with RAS-antagonists and beta-blockers compared to conventional therapy regarding the reduction of unplanned hospitalization or death due to a cardiac event in T2DM patients with a NT-proBNP \> 125pg/ml. There is an additional eye-substudy for Viennese sites only. The purpose of this sub-study is to evaluate the effect of high dose RAS-antagonists and beta blocker treatment on early subclinical signs of diabetic micro-angiopathy and neuropathy. An additional aim will be the evaluation of the possible impact of the cardiovascular risk factor NT-proBNP on the onset and progression of diabetic retinopathy.

Conditions

  • Heart Diseases
  • Diabetes Mellitus, Type 2

Interventions

  • RAS-antagonist and beta-blocker up-to maximal dosagesDrug

    All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.

  • RAS-antagonist and beta-blocker none or at stable doseOther

    All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with an unplanned cardiac hospitalization or death due to a cardiac eventTime frame: 2 years

Locations

21 sites in 5 countries. Site status is shown where the registry gives one.

  • Krankenanstalt Rudolfstiftung, 1. Medizinische Abteilung

    Vienna, Austria · Completed

  • Zentrum für Klinische Studien

    Vienna, Austria · Terminated

  • Medical University of Vienna Univ.Clinic for Internal Medicine II Department of Cardiology

    Vienna, Austria · Recruiting

  • Univ. Klinik für Innere Medizin III Med. Uni Wien

    Vienna, Austria · Recruiting

  • Universitätsklinik für Augenheilkunde und Optometrie Medizinische Universität Wien

    Vienna, Austria · Recruiting

  • Diabetes & Stoffwechselambulanz Gesundheitszentrum Wien Süd

    Vienna, Austria · Recruiting

  • 3. Med. Abtlg., KH Hietzing mit Neurologischem Zentrum Rosenhügel

    Vienna, Austria · Terminated

  • iMED19

    Vienna, Austria · Recruiting

  • Internistische Ordination

    Mödling, Lower Austria, Austria · Active not recruiting

  • Klinischen Abteilung für Endokrinologie und Diabetologie MU Graz

    Graz, Styria, Austria · Recruiting

  • Konventhospital der Barmherzigen Brüder Abteilung für Innere Medizin

    Linz, Upper Austria, Austria · Recruiting

  • Maastricht University Medical Center; Dep. Cardiology

    Maastricht, Netherlands · Active not recruiting

  • Christchurch Heart Institute

    Christchurch, New Zealand · Recruiting

  • Hospital de la Santa Creu i Sant Pau, Unitat de Diabetis, Servei d'Endocrinologia i Nutrició, Universitat Autònoma de Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitari Germans Trias i Pujol, l'Institut del Cor

    Barcelona, Spain · Recruiting

  • Ninewells Hospital, Diabetes Support Unit

    Dundee, United Kingdom · Recruiting

  • Queen Elisabeth University Hospital, Glasgow Clinical Research Facility

    Glasgow, United Kingdom · Recruiting

  • North Manchester General Hospital, Diabetes centre

    Manchester, United Kingdom · Recruiting

  • Nethergreen Surgery

    Sheffield, United Kingdom · Active not recruiting

  • Ecclesfield Group Practice

    Sheffield, United Kingdom · Active not recruiting

  • Woodseats Medical Centre

    Sheffield, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.